| 4 |
| VIKING GLOBAL INVESTORS LP |
| 5.1M |
| $55.5M |
| -12.0% |
| 4.953% |
| 0.16% |
| 5 | STATE STREET CORP | 4.9M | $53.0M | +32.2% | 4.728% | 0.00% |
| 6 | SR ONE CAPITAL MANAGEMENT, LP | 4.6M | $50.0M | +2.2% | 4.459% | 4.81% |
| 7 | Venrock Adviser, LLC | 4.3M | $46.8M | 0.0% | 4.173% | 1.42% |
| 8 | NEA Management Company, LLC | 4.1M | $44.6M | 0.0% | 3.979% | 2.81% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 4.0M | $42.8M | +7.2% | 3.817% | 0.00% |
| 10 | AIHC Capital Management Ltd | 3.8M | $41.5M | +55.7% | 3.698% | 39.77% |
| 11 | ALKEON CAPITAL MANAGEMENT LLC | 3.7M | $40.5M | -17.0% | 3.612% | 0.05% |
| 12 | Column Group LLC | 3.5M | $38.3M | 0.0% | 3.421% | 43.53% |
| 13 | Siren, L.L.C. | 3.0M | $32.5M | 0.0% | 2.896% | 0.66% |
| 14 | FMR LLC | 2.6M | $28.5M | +8.3% | 2.546% | 0.00% |
| 15 | CITADEL ADVISORS LLC | 2.6M | $28.4M | +7.8% | 2.532% | 0.00% |
| 16 | GOLDMAN SACHS GROUP INC | 2.5M | $26.6M | +66.1% | 2.369% | 0.00% |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 2.1M | $22.6M | +13.7% | 2.019% | 0.00% |
| 18 | First Turn Management, LLC | 2.0M | $21.8M | 0.0% | 1.949% | 2.34% |
| 19 | ORBIMED ADVISORS LLC | 2.0M | $21.8M | -25.2% | 1.946% | 0.40% |
| 20 | Integral Health Asset Management, LLC | 1.9M | $20.6M | +35.7% | 1.835% | 0.81% |
| 21 | MPM BioImpact LLC | 1.9M | $20.4M | +4.3% | 1.818% | 1.24% |
| 22 | Vivo Capital, LLC | 1.8M | $20.0M | 0.0% | 1.786% | 1.83% |
| 23 | DIMENSIONAL FUND ADVISORS LP | 1.8M | $19.5M | +22.4% | 1.740% | 0.00% |
| 24 | FRANKLIN TEMPLETON INC | 1.8M | $19.5M | +23.7% | 1.736% | 0.00% |
| 25 | MORGAN STANLEY | 1.8M | $19.4M | +6.6% | 1.733% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in ORIC — a direct measure of their conviction.
| 110.60% |
| +6.05 pp |
| $430M |
| 27% |
| Q4 2024 | 129 | +6.6% | 104.55% | +5.68 pp | $587M | 16% |
| Q3 2024 | 121 | — | 98.87% | — | $700M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
26 institutions opened new positions in ORIC during Q2 2026, while 29 fully exited. 57 added to existing positions and 91 trimmed.
ORIC institutional ownership rose by 4.37 percentage points quarter-over-quarter, with a net change of -2 holders.
The top 10 institutions account for 44.1% of all reported 13F value in ORIC, and the top 25 account for 74.1%.
Across the largest Oncology Biotech peers, institutional ownership levels are: DMRA (200.0%), FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.